New drug duo tested in fight against advanced blood cancers

NCT ID NCT06291987

Recruiting now Disease control Sponsor: University of Chicago Source: ClinicalTrials.gov ↗

Summary

This early-stage study is testing the safety and finding the right dose of two drugs, ivosidenib and ruxolitinib, when used together. It is for adults with advanced forms of certain blood cancers that have a specific genetic change (IDH1 mutation). The main goal is to see if the combination is safe and tolerable, while also checking for early signs that it might help control the disease.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOPROLIFERATIVE NEOPLASMS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

University of Chicago Medicine Comprehensive Cancer Center
RECRUITING

Chicago, Illinois, 60637, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

MYELOPROLIFERATIVE NEOPLASMS